Anti-human CD27 antibody and its application

By preparing anti-human CD27 antibodies with specific amino acid sequences, the problem of insufficient sensitivity and specificity of CD27 antibodies in flow cytometry detection in existing technologies has been solved, realizing efficient fine subgroup typing detection of human B cells and disease diagnosis.

CN118684778BActive Publication Date: 2024-11-08TIANJIN KUANGBO TONGSHENG BIOTECHNOLOGY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411179258.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-11-08
Estimated Expiration
2044-08-27

AI Technical Summary

Technical Problem

Existing CD27 antibodies are difficult to achieve high sensitivity and specificity in flow cytometry detection, and cannot effectively assist in the typing and disease diagnosis of fine subsets of human B cells.

Method used

An anti-human CD27 antibody is provided, containing specific heavy chain variable region and light chain variable region amino acid sequences. By preparing hybridoma cell lines and purifying the antibody, it can be used for high-sensitivity and high-specificity fine subset typing of human B cells.

Benefits of technology

A highly sensitive and specific CD27 antibody has been developed, which can effectively assist in the typing and detection of fine subsets of human B cells, thereby aiding in the diagnosis and treatment of certain diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118684778B_ABST
    Figure CN118684778B_ABST
Patent Text Reader

Abstract

The present invention provides an anti-human CD27 antibody and its application, the antibody comprises a heavy chain variable region and a light chain variable region; the CDR1, CDR2 and CDR3 of the heavy chain variable region are amino acid sequences shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3 respectively; the CDR1, CDR2 and CDR3 of the light chain variable region are amino acid sequences shown in SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6 respectively. The anti-human CD27 antibody of the present invention provides a light chain variable region and a heavy chain variable region of an anti-human CD27 monoclonal antibody, and a hybridoma cell line capable of producing CD27-specific antibodies; at the same time, the antibody has high sensitivity and high specificity, and can be used as an auxiliary for typing detection of fine subpopulations of human B cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an antibody for diagnosis and detection, in particular to an anti-human CD27 antibody and application thereof. Background Art

[0002] CD27 (tumor necrosis factor receptor superfamily member 7, TNFRSF7) is a 50-55 kD type I membrane protein, which is a lymphocyte-specific member of the TNF receptor superfamily. The protein is expressed on medullary thymocytes, almost all mature T cells, B cells and NK cells.

[0003] B cells are an important type of immune cell in the human body. They play a key role in fighting foreign invaders such as viruses, bacteria and fungi. After the initial infection, a portion of B cells will differentiate into memory B cells, retaining immune memory against specific pathogens. When the body encounters the same or similar pathogens again, memory B cells will play a vital role as new plasma cell precursors. Memory B cells can be quickly activated and rapidly differentiated into plasma cells, which can produce a large number of antibodies against the pathogen. This immune memory enables the immune system to respond more quickly and effectively to reinfection, thereby providing protection to the body. The formation of memory B cells begins in early life and continues to form and mature throughout the life of an individual. Although we still need to better understand the heterogeneity of the human memory B cell pool, studies have identified some specific cell surface markers that help distinguish different cell subsets. CD27 is one of the commonly used surface markers used to define and identify human memory B cells. It helps to distinguish different memory B cell subsets and understand their role in immune responses. CD27 antibodies are often used in combination with IgD antibodies to distinguish different B cell populations. Based on markers such as CD27 and IgD, B lymphocytes in the human body can be divided into the following four subpopulations: naive B cells (CD27-IgD + ), B cells that have undergone immune activation but have not yet fully differentiated (CD27+IgD + ), B cells that undergo immune activation, further differentiate and form memory B cells or plasma cells (CD27+IgD - ), memory B cells (CD27-IgD - ). Different subgroups of B lymphocytes have different biological characteristics and immune functions. Naive B cells are unactivated B cells that can efficiently phagocytize antigens but have only low levels of proliferation and differentiation capabilities. They are the basic B cell stock and can differentiate into memory B cells or plasma cells under antigen stimulation. CD27+IgD +B cells proliferate rapidly under antigen stimulation and transform into short-lived plasma cells or long-lived memory B cells. Memory B cells are a B cell subpopulation that is preserved in the body for a long time and has a strong immune response memory. They can quickly stimulate antibody production and have a genetic protective effect on antigens that have already been exposed. Based on the different functions of different B cell subpopulations, in clinical practice, some diseases can be assisted in diagnosis based on the proportion of different B cell subpopulations in the body. At the same time, they can be used as a reference indicator for staging some types of tumors, guiding treatment, and judging prognosis.

[0004] Flow cytometry is a powerful tool for detecting the expression of cell surface protein molecules at the single-cell level. With the help of fluorescently labeled anti-CD27 monoclonal antibodies, the expression of CD27 on the cell surface and its changes can be reflected by the presence or absence of fluorescent signals and changes in fluorescence intensity. Therefore, the development of CD27 antibodies suitable for flow cytometry detection has important application prospects in the typing detection of fine B cell subsets and the auxiliary diagnosis and treatment of diseases. Summary of the invention

[0005] In view of this, the purpose of the present invention is to provide an anti-human CD27 antibody and its application.

[0006] To achieve the above object, the technical solution of the present invention is achieved as follows:

[0007] The present invention provides an anti-human CD27 antibody, which comprises a heavy chain variable region and a light chain variable region;

[0008] The CDR1, CDR2 and CDR3 of the heavy chain variable region are the amino acid sequences shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3 respectively;

[0009] The CDR1, CDR2 and CDR3 of the light chain variable region are the amino acid sequences shown in SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6 respectively.

[0010] Furthermore, FR1, FR2, FR3, and FR4 of the heavy chain variable region are the amino acid sequences shown in SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, and SEQ ID NO.10, respectively;

[0011] The FR1, FR2, FR3 and FR4 of the light chain variable region are the amino acid sequences shown in SEQ ID NO.11, SEQ ID NO.12, SEQ ID NO.13 and SEQ ID NO.14, respectively.

[0012] Furthermore, the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO.15, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.16.

[0013] The present invention also provides a nucleic acid molecule, which comprises a nucleotide sequence encoding the anti-human CD27 antibody.

[0014] The present invention also provides an expression vector, which contains the nucleic acid molecule.

[0015] The present invention also provides a cell, which comprises one of the nucleic acid molecule or the expression vector.

[0016] The present invention also provides an immunoassay kit, which comprises the anti-human CD27 antibody.

[0017] The present invention also provides an application of the anti-human CD27 antibody, that is, the application of the anti-human CD27 antibody in preparing a detection reagent for fine subpopulation typing of human B cells.

[0018] Compared with the prior art, the present invention has the following advantages:

[0019] The anti-human CD27 antibody of the present invention provides the anti-human CD27 monoclonal antibody light chain variable region and heavy chain variable region, and a hybridoma cell line capable of producing CD27-specific antibodies; at the same time, the antibody has high sensitivity and high specificity, and can be used as an auxiliary for the typing detection of fine subpopulations of human B cells, thereby also playing an auxiliary role in the diagnosis and treatment of certain diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is the electrophoresis diagram of the purification of the anti-human CD27 antibody described in Example 5 of the present invention;

[0021] Figure 2 This is an affinity test diagram of the anti-human CD27 antibody described in Example 6 of the present invention;

[0022] Figure 3 The activity detection diagram of the anti-human CD27-APC antibody described in Example 8 of the present invention: wherein, Figure A shows commercially available antibodies distinguishing granulocytes, monocytes and lymphocytes, Figure B shows lymphocytes, Figure C shows self-screening antibodies distinguishing granulocytes, monocytes and lymphocytes, and Figure D shows lymphocytes;

[0023] Figure 4The result graphs of the application of the commercially available CD27 antibody with an addition amount of 1.0 μg in the detection of fine subpopulations of human B cells described in Example 9 of the present invention are shown in Figure A: Figure A shows the commercially available antibody distinguishing granulocytes, monocytes and lymphocytes, Figure B shows B cells, Figure C shows CD27-B and memory B cells, and Figure D shows memory B cells, DN B cells and naive B cells;

[0024] Figure 5 The results of the application of the commercially available CD27 antibody added in an amount of 0.5 μg in the detection of fine subpopulations of human B cells described in Example 9 of the present invention are shown in Figure A: Figure A shows the commercially available antibody distinguishing granulocytes, monocytes and lymphocytes, Figure B shows B cells, Figure C shows CD27-B and memory B cells, and Figure D shows memory B cells, DN B cells and naive B cells;

[0025] Figure 6 The result graphs of the application of the commercially available CD27 antibody with an addition amount of 0.25 μg in the detection of fine subpopulations of human B cells described in Example 9 of the present invention are shown in Figure A: wherein, Figure A shows the commercially available antibody distinguishing granulocytes, monocytes and lymphocytes, Figure B shows B cells, Figure C shows CD27-B and memory B cells, and Figure D shows memory B cells, DN B cells and naive B cells;

[0026] Figure 7 The results of the application of the self-screening CD27 antibody added in an amount of 1.0 μg in the detection of fine subpopulations of human B cells described in Example 9 of the present invention are shown in Figure A: wherein, Figure A shows the self-screening antibody distinguishing granulocytes, monocytes and lymphocytes, Figure B shows B cells, Figure C shows CD27-B and memory B cells, and Figure D shows memory B cells, DN B cells and naive B cells;

[0027] Figure 8 The result graphs of the application of the self-screening CD27 antibody added in an amount of 0.5 μg in the detection of fine subpopulations of human B cells described in Example 9 of the present invention are shown in Figure A: Figure A shows the self-screening antibody distinguishing granulocytes, monocytes and lymphocytes, Figure B shows B cells, Figure C shows CD27-B and memory B cells, and Figure D shows memory B cells, DN B cells and naive B cells;

[0028] Fig. 9 The result graphs of the application of the self-screening CD27 antibody with an addition amount of 0.25 μg as described in Example 9 of the present invention in the detection of fine subpopulations of human B cells are shown below: wherein, Figure A shows the self-screening antibody distinguishing granulocytes, monocytes and lymphocytes, Figure B shows B cells, Figure C shows CD27-B and memory B cells, and Figure D shows memory B cells, DN B cells and initial B cells. DETAILED DESCRIPTION

[0029] Unless otherwise defined, the technical terms used in the following examples have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. The test reagents used in the following examples, unless otherwise specified, are all conventional biochemical reagents; the experimental methods, unless otherwise specified, are all conventional methods.

[0030] The present invention will be described in detail below with reference to the embodiments.

[0031] Example 1 Cloning of anti-human CD27 antigen sequences

[0032] The lentiviral expression vector used in this example is constructed by inserting the CD27 gene (encoding human CD27 protein) into the multiple cloning site of pCDH-CMV-MCS-EF1-copGFP as an empty vector (GENE ID: NM_001242.5, https: / / www.ncbi.nlm.nih.gov / nuccore / NM_001242.5), and preparing packaging vectors pMD2.G and psPAX2 at the same time. The plasmid was extracted using a plasmid mini-extraction kit, and the obtained target plasmid was frozen and stored in a -20°C refrigerator to avoid repeated freezing and thawing.

[0033] Example 2 Lentivirus Coating and Immune Cell Preparation Carrying Human CD27 Antigen Sequence

[0034] 1. Lentivirus coating: Collect 293T cells in the proliferation stage with normal cell morphology and evenly spread them in a cell culture dish; the next day, use the three previously extracted plasmids and transfection reagents to mix in a certain proportion; gently and evenly add the plasmid-transfection reagent mixture after incubation to the 293T cells to avoid blowing the cells; after 48-72 hours of culture, collect the supernatant to obtain the virus; then use a high-speed centrifuge to concentrate the virus; the concentrated virus is directly used for subsequent infection experiments, or packaged in small volumes and stored in a -80℃ refrigerator.

[0035] 2. Infect 3T3 cells with lentivirus: 3T3 cells in the logarithmic growth phase were inoculated into 24-well culture plates and cultured in an incubator overnight. The next day, concentrated lentivirus was added to the well plate containing cells, and polybrene was added to promote infection. The cells were gently mixed and cultured in an incubator. After a few days, the GFP fluorescence intensity of 3T3 cells was observed under a filter. After the ideal brightness was obtained, the cells were cultured and expanded. The cells were named CD27-3T3.

[0036] 3. Flow cytometry analysis of lentiviral infection efficiency: Collect CD27-3T3 cells that have been amplified after infection, and obtain the positive rate data of the cells by using antibody labeling and flow cytometry detection; when the cell positive rate reaches more than 95%, it can be used to immunize animals.

[0037] Example 3 Animal Immunization

[0038] CD27-3T3 cells in the logarithmic growth phase were collected as immunogens and immunized 4-5 week old female BALB / c mice by intraperitoneal injection; booster immunizations were performed at the 3rd and 5th weeks after the initial immunization; and the serum of the mice was then tested for titer.

[0039] Example 4 Cell fusion and screening

[0040] 1. Three days before fusion, mice were immunized by tail vein injection; on the day of fusion, mice with high immune titers were selected, the spleens of mice were carefully removed in a biosafety cabinet, and the spleens were ground to collect spleen cells; SP2 / 0 cells in good growth state in the logarithmic growth phase were collected at the same time, and SP2 / 0 cells were mixed with spleen cells in a certain proportion to prepare for fusion; the fusion process should be carried out in a 37°C water bath environment, and PEG was used to fuse the cells; after fusion, the cells were resuspended in a special culture medium, and the cells were plated in a flat-bottom 96-well plate and cultured in a cell culture incubator.

[0041] 2. Screening of hybridoma cells and subclones that secrete antibodies that specifically target CD27: When the cell clones are large enough under a microscope, take the supernatant of the corresponding wells for flow cytometry detection; when a positive well is screened, expand the culture of the well and retest. If the test result is still positive, perform a round of subcloning using the limiting dilution method. If the test result is negative, discard it; clones that are still positive in the first round of subcloning will continue to undergo a second round of subcloning; clones that are positive in the second round of subcloning will undergo a third round of subcloning. Generally, at least three rounds of subcloning are performed, and the clones obtained from the three rounds of subcloning are all positive clones, that is, a stable hybridoma cell line is obtained.

[0042] Example 5 Preparation and purification of anti-human CD27 antibodies

[0043] 1. Production of monoclonal antibodies in mice: Collect hybridoma cells in good growth state and inject them into the mouse peritoneum; when the abdomen of the mouse is obviously swollen, start collecting ascites; freeze the collected ascites at -20℃.

[0044] 2. Purification of anti-human CD27 antibody: Purify the ascites collected in the previous step using a Protein A affinity column. After equilibration of the column with PBS, load the sample and elute with glycine at pH 3.0. Elute the pure antibody using a G25 column to replace the solution. Replace the solution with PBS, then aliquot and freeze at -20°C. The purified electrophoresis is shown in the following figure: Figure 1 shown.

[0045] Example 6 Affinity determination of anti-human CD27 antibodies

[0046] Normal human peripheral blood test: 100 μL normal human anticoagulated peripheral blood was added to each tube, and different amounts of CD27 antibody and commercially available CD27 antibody (purchased from Biolegend) were added respectively. After incubation at room temperature for 30 minutes, the tube was centrifuged at 1000 rpm for 5 minutes, and the supernatant was discarded; PBS buffer was added for resuspending, and the tube was centrifuged at 1000 rpm for 5 minutes, and the supernatant was discarded; 0.5 μg APC-labeled secondary antibody was added, and the tube was incubated at room temperature in the dark for 30 minutes; 2 mL hemolysin was added for reaction at room temperature in the dark for 10 minutes, and the tube was centrifuged at 1000 rpm for 5 minutes, and the supernatant was discarded; matching CD45-PerCP and CD3-FITC were added; the tube was incubated at room temperature in the dark for 30 minutes; 2 mL cold PBS buffer was added, and the tube was centrifuged at 1000 rpm for 5 minutes, and the supernatant was discarded; 300 μL PBS buffer containing 1% paraformaldehyde was added, and the tube was detected by flow cytometry.

[0047] The antibody affinity data was obtained through GraphPad analysis. The principle of GraphPad analysis is: when using different concentrations of antibodies for flow cytometry detection, the antibody concentration corresponding to half of the sum of the highest fluorescence intensity and the lowest fluorescence intensity. At half of the sum of the highest fluorescence intensity (14825) and the lowest fluorescence intensity (3261), the antibody dosage corresponding to the CD27 antibody prepared by the present invention is 0.500μg / mL, which is converted into an antibody dosage of 0.24μg. The antibody dosage corresponding to the CD27 control antibody is 0.216μg / mL, which is converted into an antibody dosage of 0.104μg. The flow cytometer test results are converted into a line graph with the antibody dosage for each test (each test volume is 120 microliters) as the horizontal axis and the fluorescence intensity as the vertical axis as shown in the figure. Figure 2 As shown, since the usual usage of antibodies is between 0.5-0.125 μg, it can be seen from the line graph that in this concentration range, the performance of self-screened antibodies is better than that of commercially available antibodies.

[0048] Example 7 APC Labeling of Anti-Human CD27 Antibody

[0049] The anti-human CD27 antibody and the commercially available CD27 antibody were reduced using a reducing agent, respectively, and then mixed evenly with the activated APC, stirred at 25° C., and reacted for 1 hour; and then purified using an S200 increase purification column to obtain the APC-labeled CD27 antibody.

[0050] Example 8 Activity determination of anti-human CD27-APC antibody

[0051] Normal human peripheral blood test: add 100μl normal human anticoagulated peripheral blood to each tube, add different amounts of antibody CD27-APC (1.0μg, 0.5μg, 0.25, 0.13μg, 0.06μg, 0.03μg), then add antibody CD45-PerCP, CD3-FITC, incubate at room temperature in the dark for 30 minutes; add 2ml hemolysin, react at room temperature in the dark for 10 minutes, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant; add 2ml cold PBS buffer, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant; add 300μl PBS buffer, and the scatter plot results of flow cytometry detection are as follows Figure 3 As shown. Figure 3 It can be seen that at the same antibody addition amount (0.5 μg), the self-screening antibody (CD27 antibody prepared by the present invention) performs the same as the commercially available antibody in terms of cell clustering, and the percentages of each subgroup are also basically the same. That is, the self-screening antibody can achieve the same detection effect as the commercially available antibody.

[0052] Example 9 Application of anti-human CD27-APC antibody in the detection of human B cell subpopulations

[0053] Normal human peripheral blood test: add 100μl normal human anticoagulated peripheral blood to each tube, add different amounts of antibody CD27-APC (1.0μg, 0.5μg, 0.25, 0.13μg, 0.06μg, 0.03μg), then add antibodies CD3-PE-Cy7, IgD-PerCP-Cy5.5 and CD45-QB500, incubate at room temperature in the dark for 30 minutes; add 2ml hemolysin, react at room temperature in the dark for 10 minutes, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant; add 2ml cold PBS buffer, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant; add 300μl PBS buffer, and detect by flow cytometry. The test results are as follows: Figure 4-Figure 9 shown. Figure 4-Figure 6 This is a graph showing the results of grouping normal human anticoagulated peripheral blood using commercially available antibodies; Figure 7-Figure 9 The figure shows the results of the self-screening antibody testing the anticoagulated peripheral blood of normal people. From the above results, it can be concluded that after being used in combination with IgD antibodies, the self-screening antibodies and commercial antibodies have the same detection grouping and percentage results when added in the same amount, that is, the self-screening antibodies can achieve the same detection effect as commercial antibodies.

[0054] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. An anti-human CD27 antibody, characterized in that: The antibody comprises a heavy chain variable region and a light chain variable region; The CDR1, CDR2 and CDR3 of the heavy chain variable region are the amino acid sequences shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3 respectively; The CDR1, CDR2 and CDR3 of the light chain variable region are the amino acid sequences shown in SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6 respectively.

2. The anti-human CD27 antibody according to claim 1, characterized in that: The FR1, FR2, FR3, and FR4 of the heavy chain variable region are the amino acid sequences shown in SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, and SEQ ID NO.10, respectively; The FR1, FR2, FR3 and FR4 of the light chain variable region are the amino acid sequences shown in SEQ ID NO.11, SEQ ID NO.12, SEQ ID NO.13 and SEQ ID NO.14, respectively.

3. The anti-human CD27 antibody according to claim 1, characterized in that: The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO.15, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.

16.

4. A nucleic acid molecule, characterized in that: The nucleic acid molecule is a nucleotide sequence encoding the anti-human CD27 antibody according to any one of claims 1 to 3.

5. An expression vector, characterized in that: The expression vector comprises the nucleic acid molecule according to claim 4.

6. A cell, characterized in that: The cell comprises the nucleic acid molecule of claim 4 or the expression vector of claim 5.

7. An immunoassay kit, characterized in that: The kit comprises the anti-human CD27 antibody according to any one of claims 1 to 3.

8. The use of the anti-human CD27 antibody according to any one of claims 1 to 3, characterized in that: The anti-human CD27 antibody is used in preparing a detection reagent for fine subpopulation typing of human B cells.